SE9101642D0
(sv)
*
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
DK198991D0
(da)
*
|
1991-12-10 |
1991-12-10 |
Simanol A S |
Fiskeprodukt
|
SE9200541D0
(sv)
*
|
1992-02-24 |
1992-02-24 |
Kabi Pharmacia Ab |
New usee of omega-3-fatty acids
|
US5719302A
(en)
*
|
1993-04-29 |
1998-02-17 |
Pronova A.S |
Processes for chromatographic fractionation of fatty acids and their derivatives
|
US20050027004A1
(en)
*
|
1993-06-09 |
2005-02-03 |
Martek Biosciences Corporation |
Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
|
US5767156A
(en)
*
|
1993-10-06 |
1998-06-16 |
Peptide Technology Limited |
Polyunsaturated fatty acids and uses thereof
|
IT1264987B1
(it)
*
|
1993-12-14 |
1996-10-17 |
Prospa Bv |
Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono
|
GB9404483D0
(en)
*
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
IT1274734B
(it)
*
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
EP1886679A3
(en)
*
|
1995-06-07 |
2008-05-28 |
Martek Biosciences Corporation |
Methods for controlling highly unsaturated fatty acid content in various tissues
|
DK0862369T4
(da)
*
|
1995-11-24 |
2009-12-14 |
Unilever Nv |
Sammensætning baseret på fiskeolie
|
US5866150A
(en)
*
|
1996-03-20 |
1999-02-02 |
Aquaculture Technology Incorporated |
Antibacterially active extracts from the marine algae chaetoceros and methods of use
|
EP1004303B1
(en)
|
1997-06-16 |
2004-10-13 |
Nippon Suisan Kaisha, Ltd. |
Composition having capability of removing risk factor during exercise
|
IL121165A0
(en)
*
|
1997-06-26 |
1997-11-20 |
Yissum Res Dev Co |
Pharmaceutical compositions containing carboxylic acids and derivatives thereof
|
US20020037876A1
(en)
*
|
1998-06-25 |
2002-03-28 |
Yissum Research Development Company Of Hebrew University Of Jerusalem |
Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
|
EP1025190A2
(en)
*
|
1997-10-23 |
2000-08-09 |
The Procter & Gamble Company |
Fatty acids, soaps, surfactant systems, and consumer products based thereon
|
US6992057B2
(en)
*
|
2000-02-22 |
2006-01-31 |
The Procter & Gamble Company |
Fatty acids, soaps, surfactant systems, and consumer products based thereon
|
NO309795B1
(no)
*
|
1998-07-01 |
2001-04-02 |
Norsk Hydro As |
FremgangsmOte for O stabilisere oljer samt anvendelse derav, fremgangsmOte for O stabilisere pigmenter, og fremgangsmOte for fremstilling av for
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
IT1308613B1
(it)
*
|
1999-02-17 |
2002-01-09 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
|
US7112609B2
(en)
*
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
US6998501B1
(en)
|
1999-08-30 |
2006-02-14 |
Ocean Nutrition Canada Limited |
Nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
WO2001051598A1
(en)
|
2000-01-11 |
2001-07-19 |
Monsanto Technology Llc |
Process for making an enriched mixture of polyunsaturated fatty acid esters
|
US20020016314A1
(en)
*
|
2000-01-31 |
2002-02-07 |
Schersl Endre Markovits |
Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides
|
CA2304906A1
(en)
*
|
2000-04-07 |
2001-10-07 |
1411198 Ontario Limited |
13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
|
ATE305810T1
(de)
*
|
2000-05-22 |
2005-10-15 |
Pro Aparts Investimentos E Con |
Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
|
US6667064B2
(en)
|
2000-08-30 |
2003-12-23 |
Pilot Therapeutics, Inc. |
Composition and method for treatment of hypertriglyceridemia
|
ITMI20010129A1
(it)
*
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
ITMI20012384A1
(it)
*
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
US8729124B2
(en)
*
|
2002-03-05 |
2014-05-20 |
Pronova Biopharma Norge As |
Use of EPA and DHA in secondary prevention
|
NZ518504A
(en)
*
|
2002-04-22 |
2005-05-27 |
Ind Res Ltd |
Use of near-critical fluids in the separation of saturated and mono-unsaturated fatty acids from urea-containing solutions
|
AU2003240189A1
(en)
*
|
2002-06-17 |
2003-12-31 |
Medestea Research And Production S.R.L. |
Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field
|
SE0202188D0
(sv)
|
2002-07-11 |
2002-07-11 |
Pronova Biocare As |
A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
|
EP2295529B2
(en)
|
2002-07-11 |
2022-05-18 |
Basf As |
Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
|
US7279018B2
(en)
|
2002-09-06 |
2007-10-09 |
Fortum Oyj |
Fuel composition for a diesel engine
|
US7041840B2
(en)
*
|
2002-12-18 |
2006-05-09 |
Alberta Research Council Inc. |
Antioxidant triacylglycerols and lipid compositions
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
US20040235948A1
(en)
*
|
2003-03-05 |
2004-11-25 |
Solvay Pharmaceuticals Gmbh |
Treatment of diabetic patients with omega-3-fatty acids
|
DE10317109A1
(de)
*
|
2003-04-14 |
2004-11-11 |
Cognis Deutschland Gmbh & Co. Kg |
Zubereitungen zur oralen Aufnahme
|
US7759507B2
(en)
*
|
2003-09-05 |
2010-07-20 |
Abbott Laboratories |
Lipid system and methods of use
|
US8052992B2
(en)
*
|
2003-10-22 |
2011-11-08 |
Enzymotec Ltd. |
Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
|
SE0303513D0
(sv)
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
ITMI20040069A1
(it)
|
2004-01-21 |
2004-04-21 |
Tiberio Bruzzese |
Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
|
GB0403247D0
(en)
*
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
US7022713B2
(en)
*
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
EP1600060A1
(en)
|
2004-05-25 |
2005-11-30 |
Cognis IP Management GmbH |
Oral and/or topical compositions comprising prebiotics and fatty acid
|
US20060020031A1
(en)
*
|
2004-07-26 |
2006-01-26 |
Roger Berlin |
Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses
|
KR20070052760A
(ko)
*
|
2004-08-06 |
2007-05-22 |
트렌스폼 파마수티컬스 인코퍼레이티드 |
신규한 페노피브레이트 제제 및 관련된 치료방법
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
EP1656934A1
(en)
*
|
2004-11-12 |
2006-05-17 |
Cognis IP Management GmbH |
Use of physiologically active fatty acids for treating lipodystrophy
|
EP1656935A1
(en)
*
|
2004-11-12 |
2006-05-17 |
Cognis IP Management GmbH |
Use of physiologically active fatty acids for the treatment of pruritus
|
CN101098690A
(zh)
*
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
WO2006062748A2
(en)
*
|
2004-12-06 |
2006-06-15 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
|
US20060135610A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
WO2006096806A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Reliant Pharmaceutiacals, Inc. |
Treatment with statin and omega-3 fatty acids and a combination product thereof
|
CN101213281B
(zh)
*
|
2005-05-04 |
2013-03-13 |
普罗诺瓦生物医药挪威公司 |
新的dha衍生物及其作为药物的用途
|
CN102050720B
(zh)
*
|
2005-05-04 |
2013-03-13 |
普罗诺瓦生物医药挪威公司 |
新的dha衍生物及其作为药物的用途
|
JP5046926B2
(ja)
*
|
2005-05-16 |
2012-10-10 |
日本水産株式会社 |
炎症性疾患予防又は治療剤
|
US20060292217A1
(en)
*
|
2005-06-03 |
2006-12-28 |
Schmidt Robbin D |
Nutritional supplement and soft gelatin capsule delivery system
|
MX2008001282A
(es)
*
|
2005-07-28 |
2008-03-24 |
Reliant Pharmaceuticals Inc |
Tratamiento con bloqueadores del canal del calcio de dihidropiridina y acidos grasos omega-3 y un producto de combinacion de los mismos.
|
ITMI20051560A1
(it)
*
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
DE102005040463A1
(de)
|
2005-08-26 |
2007-03-01 |
Cognis Ip Management Gmbh |
Verwendung von Gemischen aus Polyphenolen und physiologisch aktiven ungesättigten Fettstoffen
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
US20070104779A1
(en)
*
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
DE102005054577A1
(de)
|
2005-11-16 |
2007-05-24 |
Cognis Ip Management Gmbh |
Verwendung von Estern ungesättigter, physiologisch aktiver Fettsäuren als Nährmedien für Zellkulturen
|
KR20080073288A
(ko)
*
|
2005-12-09 |
2008-08-08 |
드러그테크 코포레이션 |
정맥내 필수 지방산 에멀젼
|
MX286464B
(es)
*
|
2005-12-20 |
2011-05-10 |
Cenestra Llc |
Formulaciones de acido graso omega 3.
|
WO2007081773A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Reliant Pharmaceuticals, Inc |
Treatment of fatty liver
|
EP1991196B1
(en)
|
2006-03-03 |
2016-10-12 |
Fmc Corporation |
Method and apparatus for the preparation of capsules.
|
JP5628480B2
(ja)
|
2006-03-09 |
2014-11-19 |
グラクソスミスクライン エルエルシー |
医薬成分を含有するコーティングカプセル
|
US8784886B2
(en)
*
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
ES2500063T3
(es)
*
|
2006-05-31 |
2014-09-29 |
Mochida Pharmaceutical Co., Ltd. |
Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple
|
EP2068861A4
(en)
*
|
2006-07-21 |
2010-01-06 |
Reliant Pharmaceuticals Inc |
COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USE THEREOF IN THE TREATMENT OF PERIPHERAL ARTERIES DISEASE AND INTERMITTENT CLAUDICATION
|
EP2083622A4
(en)
*
|
2006-10-18 |
2009-12-09 |
Reliant Pharmaceuticals Inc |
METHODS OF USING OMEGA-3 FATTY ACIDS TO REDUCE LP-PLA2 RATES
|
BRPI0717883A2
(pt)
|
2006-11-01 |
2013-10-29 |
Pronova Biopharma Norge As |
Compostos lipídicos, composição contendo os mesmos e uso dos referidos compostos
|
CN101631757A
(zh)
*
|
2006-11-01 |
2010-01-20 |
普罗诺瓦生物医药挪威公司 |
ω-3脂质化合物
|
BRPI0717972A2
(pt)
*
|
2006-11-01 |
2013-11-12 |
Pronova Biopharma Norge As |
Lipídeos de ômega-3 alfa-substituídos que são ativadores ou moduladores do receptor ativado por proliferadores de peroxissoma (ppar)
|
CA2667211A1
(en)
*
|
2006-11-01 |
2008-05-08 |
Pronova Biopharma Norge As |
Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
|
US20080125490A1
(en)
*
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
WO2008139261A2
(en)
*
|
2006-11-03 |
2008-11-20 |
Pronova Biopharma Norge As |
Omega-3 lipid compound
|
US20080306154A1
(en)
*
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
US20100130611A1
(en)
*
|
2006-12-20 |
2010-05-27 |
Cenestra Llc |
Omega 3 fatty acid formulations
|
EP1967197A1
(en)
*
|
2007-03-09 |
2008-09-10 |
Cognis IP Management GmbH |
Use of preparations, purifications and extracts of aloe
|
JP2010532418A
(ja)
*
|
2007-06-29 |
2010-10-07 |
マーテック バイオサイエンシーズ コーポレーション |
多価不飽和脂肪酸のエステルの製造方法および精製方法
|
US20100119598A1
(en)
*
|
2007-06-29 |
2010-05-13 |
Takeda Pharmaceutical Company Limited |
Seamless capsule
|
US20090011012A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Baum Seth J |
Fatty acid compositions and methods of use
|
ES2748136T3
(es)
|
2007-10-15 |
2020-03-13 |
United Animal Health Inc |
Método para aumentar el rendimiento de las crías
|
WO2009056983A1
(en)
*
|
2007-10-31 |
2009-05-07 |
Pronova Biopharma Norge As |
New dha derivatives and their use as medicaments
|
US20100010088A1
(en)
*
|
2007-11-01 |
2010-01-14 |
Wake Forest University School Of Medicine |
Compositions and Methods for Prevention and Treatment of Mammalian Diseases
|
US8343753B2
(en)
*
|
2007-11-01 |
2013-01-01 |
Wake Forest University School Of Medicine |
Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
|
WO2009070589A1
(en)
*
|
2007-11-30 |
2009-06-04 |
Jbs United, Inc. |
Method and composition for treating pulmonary hemorrhage
|
US8575409B2
(en)
|
2007-12-20 |
2013-11-05 |
Syntroleum Corporation |
Method for the removal of phosphorus
|
US20100285121A1
(en)
|
2008-01-10 |
2010-11-11 |
Takeda Pharmaceutical Company Limited |
Capsule Formulation
|
US20090182049A1
(en)
*
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
WO2009139641A1
(en)
|
2008-05-15 |
2009-11-19 |
Pronova Biopharma Norge As |
Krill oil process
|
US8581013B2
(en)
|
2008-06-04 |
2013-11-12 |
Syntroleum Corporation |
Biorenewable naphtha composition and methods of making same
|
US20090300971A1
(en)
|
2008-06-04 |
2009-12-10 |
Ramin Abhari |
Biorenewable naphtha
|
SI2323647T1
(sl)
|
2008-08-07 |
2015-01-30 |
Spa Societa'prodotti Antibiotici S.P.A. |
Dolgotrajno zdravljenje simptomatskega srčnega popuščanja
|
ES2862336T3
(es)
|
2008-09-02 |
2021-10-07 |
Amarin Pharmaceuticals Ie Ltd |
Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
|
US20100062057A1
(en)
*
|
2008-09-10 |
2010-03-11 |
Pronova BioPharma Norge AS. |
Formulation
|
WO2010040012A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
US8231804B2
(en)
|
2008-12-10 |
2012-07-31 |
Syntroleum Corporation |
Even carbon number paraffin composition and method of manufacturing same
|
WO2010077967A1
(en)
*
|
2008-12-16 |
2010-07-08 |
Cetane Energy, Llc |
Systems and methods of generating renewable diesel
|
JP2012514596A
(ja)
|
2009-01-05 |
2012-06-28 |
カラナス エーエス |
バイオオイル組成物、上記オイル組成物を含む製剤と、循環器疾患の予防又は治療のためのその使用
|
CA2751576C
(en)
|
2009-02-10 |
2018-07-03 |
Amarin Pharma, Inc. |
Use of eicosapentaenoic acid to treat hypertriglyceridemia
|
EA022028B1
(ru)
|
2009-03-09 |
2015-10-30 |
Пронова Биофарма Норге Ас |
Композиции, содержащие масляную смесь жирных кислот и поверхностно-активное вещество, способы и применения композиций
|
US20110071090A1
(en)
*
|
2009-03-11 |
2011-03-24 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
|
US8241672B2
(en)
*
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US9034389B2
(en)
|
2009-03-11 |
2015-05-19 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US8993625B2
(en)
|
2009-03-11 |
2015-03-31 |
Stable Solutions Llc |
Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
|
AU2009344374B2
(en)
*
|
2009-04-17 |
2015-07-23 |
Natac Pharma S.L. |
Compositions rich in omega-3 fatty acids with a low content in phytanic acid
|
SI2424356T1
(en)
|
2009-04-29 |
2018-01-31 |
Armarin Pharmaceuticals Ireland Limited |
A stable pharmaceutical composition and procedures for its use
|
KR101357438B1
(ko)
|
2009-04-29 |
2014-02-06 |
아마린 코포레이션 피엘씨 |
Epa 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법
|
MY172372A
(en)
|
2009-06-15 |
2019-11-21 |
Amarin Pharmaceuticals Ie Ltd |
Compositions and methods for lowering triglycerides
|
US9101942B2
(en)
|
2009-06-16 |
2015-08-11 |
Aurora Algae, Inc. |
Clarification of suspensions
|
US20110033531A1
(en)
*
|
2009-08-10 |
2011-02-10 |
Dracopharma, Inc. |
Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
|
US20110033595A1
(en)
*
|
2009-08-10 |
2011-02-10 |
Rudolf Krumbholz |
Fatty acid fractionation process, fatty acid products and use thereof
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
US8980312B2
(en)
*
|
2009-09-10 |
2015-03-17 |
Fmc Corporation |
Seamless alginate capsules
|
EP2480248B1
(en)
|
2009-09-23 |
2015-09-02 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
US20110082205A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Panker Cynthia A |
Docosahexaenoic Acid Gel Caps
|
EP2488022B1
(en)
|
2009-10-16 |
2018-01-10 |
Mochida Pharmaceutical Co., Ltd. |
Compositions
|
KR101904388B1
(ko)
*
|
2009-10-23 |
2018-10-05 |
프로노바 바이오파마 너지 에이에스 |
지방산 오일 혼합물의 코팅된 캡슐 및 정제
|
AU2013204090B2
(en)
*
|
2009-12-30 |
2015-01-29 |
Basf Pharma (Callanish) Limited |
Simulated moving bed chromatographic separation process
|
EP2591778B1
(en)
|
2009-12-30 |
2021-01-20 |
BASF Pharma (Callanish) Limited |
Polyunsaturated fatty acid compositions obtainable by a simulated moving bed chromatographic separation process
|
WO2011087981A2
(en)
|
2010-01-15 |
2011-07-21 |
E. I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
WO2011109724A1
(en)
*
|
2010-03-04 |
2011-09-09 |
Amarin Pharma, Inc. |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US8394900B2
(en)
|
2010-03-18 |
2013-03-12 |
Syntroleum Corporation |
Profitable method for carbon capture and storage
|
US8563609B2
(en)
|
2010-05-13 |
2013-10-22 |
Nitromega Corp. |
Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
|
ITMI20100961A1
(it)
*
|
2010-05-27 |
2011-11-28 |
Erredue Spa |
Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
|
WO2012009707A2
(en)
*
|
2010-07-16 |
2012-01-19 |
Atrium Medical Corporation |
Composition and methods for altering the rate of hydrolysis of cured oil-based materials
|
AR082930A1
(es)
*
|
2010-09-08 |
2013-01-16 |
Pronova Biopharma Norge As |
Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
|
US20140004186A1
(en)
*
|
2010-09-08 |
2014-01-02 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
|
JP2013537186A
(ja)
*
|
2010-09-08 |
2013-09-30 |
プロノヴァ・バイオファーマ・ノルゲ・アーエス |
脂肪酸油混合物と遊離脂肪酸とスタチンとを含む組成物
|
EP2646013A4
(en)
|
2010-11-29 |
2014-03-26 |
Amarin Pharma Inc |
COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
CL2010001587A1
(es)
*
|
2010-12-27 |
2013-01-11 |
Golden Omega S A |
Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
|
US8951514B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
|
US8952000B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
|
US8715648B2
(en)
|
2011-02-16 |
2014-05-06 |
Pivotal Therapeutics Inc. |
Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
|
US9119826B2
(en)
|
2011-02-16 |
2015-09-01 |
Pivotal Therapeutics, Inc. |
Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
|
EP2540292A1
(en)
*
|
2011-06-28 |
2013-01-02 |
Nestec S.A. |
DHA and EPA in the reduction of oxidative stress
|
US8865685B2
(en)
|
2011-06-30 |
2014-10-21 |
Johnson & Johnson Vision Care, Inc. |
Esters for treatment of ocular inflammatory conditions
|
GB201111591D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
Further new process
|
GB201111595D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
Improved process
|
GB201111601D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New process
|
GB201111589D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New modified process
|
GB201111594D0
(en)
|
2011-07-06 |
2011-08-24 |
Equateq Ltd |
New improved process
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
WO2013068443A1
(en)
|
2011-11-09 |
2013-05-16 |
Sondboe Sverre |
Membrane-based processes for reducing at least one impurity and making a concentrate comprising at least one natural component from a non-marine fatty acid oil mixture, and compositions resulting thereof
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
WO2013072767A1
(en)
|
2011-11-18 |
2013-05-23 |
Pronova Biopharma Norge As |
Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
|
AU2013201793B2
(en)
*
|
2012-01-06 |
2015-03-19 |
Chrysalis Pharma Ag |
DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
|
EP2800469B1
(en)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
EP3348262A1
(en)
|
2012-01-06 |
2018-07-18 |
Omthera Pharmaceuticals Inc. |
Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
|
WO2013130411A1
(en)
|
2012-02-27 |
2013-09-06 |
Essentialis, Inc. |
Salts of potassium atp channel openers and uses thereof
|
US20160228397A1
(en)
|
2012-03-30 |
2016-08-11 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions
|
US10898458B2
(en)
|
2012-03-30 |
2021-01-26 |
Micelle Biopharma, Inc. |
Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
|
MX359711B
(es)
|
2012-03-30 |
2018-10-08 |
Sancilio & Company Inc |
Composiciones de éster de ácido graso omega-3.
|
US9480651B2
(en)
|
2012-03-30 |
2016-11-01 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
|
US8652518B2
(en)
|
2012-04-15 |
2014-02-18 |
Jahahreeh Finley |
Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
|
ES2655622T3
(es)
|
2012-04-30 |
2018-02-20 |
Tillotts Pharma Ag |
Una formulación de fármaco de liberación retardada
|
EP2846779A4
(en)
*
|
2012-05-07 |
2015-12-16 |
Omthera Pharmaceuticals Inc |
STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS
|
CN107602378B
(zh)
*
|
2012-05-14 |
2021-06-25 |
日本水产株式会社 |
高度不饱和脂肪酸或高度不饱和脂肪酸乙酯及其制造方法、药品、添加剂或食品
|
EP2861227A4
(en)
*
|
2012-06-17 |
2016-01-27 |
Matinas Biopharma Inc |
OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
|
MX2020008890A
(es)
|
2012-06-29 |
2022-08-15 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
|
US20140088047A1
(en)
|
2012-09-24 |
2014-03-27 |
Aker Bioassist As |
Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease
|
EP3756658A1
(en)
|
2012-09-24 |
2020-12-30 |
Aker Biomarine Antarctic As |
Omega -3 compositions
|
JP2016500055A
(ja)
*
|
2012-10-23 |
2016-01-07 |
ディーキン・ユニバーシティー |
トリグリセリドを低減させる方法
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
MX2015007082A
(es)
*
|
2012-12-06 |
2016-01-12 |
Matinas Biopharma Inc |
Métodos de administración de composiciones que comprenden ácido docosapentanoico.
|
US9629820B2
(en)
|
2012-12-24 |
2017-04-25 |
Qualitas Health, Ltd. |
Eicosapentaenoic acid (EPA) formulations
|
US10123986B2
(en)
|
2012-12-24 |
2018-11-13 |
Qualitas Health, Ltd. |
Eicosapentaenoic acid (EPA) formulations
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
GB201300354D0
(en)
|
2013-01-09 |
2013-02-20 |
Basf Pharma Callanish Ltd |
Multi-step separation process
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
WO2014134053A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Jiva Pharma, Inc. |
Ascorbate esters of omega-3 fatty acids
|
US9328303B2
(en)
|
2013-03-13 |
2016-05-03 |
Reg Synthetic Fuels, Llc |
Reducing pressure drop buildup in bio-oil hydroprocessing reactors
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US20140275613A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Aurora Algae, Inc. |
Conversion of free fatty acids to ethyl esters
|
US9266973B2
(en)
|
2013-03-15 |
2016-02-23 |
Aurora Algae, Inc. |
Systems and methods for utilizing and recovering chitosan to process biological material
|
US8969259B2
(en)
|
2013-04-05 |
2015-03-03 |
Reg Synthetic Fuels, Llc |
Bio-based synthetic fluids
|
US9428711B2
(en)
|
2013-05-07 |
2016-08-30 |
Groupe Novasep |
Chromatographic process for the production of highly purified polyunsaturated fatty acids
|
US8802880B1
(en)
|
2013-05-07 |
2014-08-12 |
Group Novasep |
Chromatographic process for the production of highly purified polyunsaturated fatty acids
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
WO2015011724A2
(en)
|
2013-07-22 |
2015-01-29 |
Kms Health Center Pvt Ltd |
A novel omega -3 fatty acid composition with a plant extract
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
CN110279669B
(zh)
|
2013-10-29 |
2022-02-15 |
狄洛特医药有限公司 |
延迟释放的药物制剂
|
ES2826201T3
(es)
|
2013-10-30 |
2021-05-17 |
Patheon Softgels Inc |
Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados
|
EP3066183A4
(en)
*
|
2013-11-08 |
2017-09-27 |
Omega Protein Corporation |
Purification of dpa enriched oil
|
EP2883860B1
(fr)
|
2013-12-11 |
2016-08-24 |
Novasep Process |
Procédé chromatographique de production d'acides gras polyinsaturés
|
BR112016015718B1
(pt)
|
2014-01-07 |
2021-12-07 |
Novasep Process Solutions |
Processo de purificação de aminoácidos aromáticos
|
KR102400958B1
(ko)
|
2014-06-06 |
2022-05-20 |
마린 인그리디언츠, 엘엘씨 |
오메가-3 조성물, 제형 및 사용 방법
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US9895333B2
(en)
*
|
2014-06-26 |
2018-02-20 |
Patheon Softgels Inc. |
Enhanced bioavailability of polyunsaturated fatty acids
|
TWI532482B
(zh)
*
|
2014-09-01 |
2016-05-11 |
國立中山大學 |
阿魏酸用以製備提升血紅蛋白釋放氧氣至人體內各器官及周邊組織能力之藥物的用途
|
CN107666904B
(zh)
*
|
2015-03-26 |
2022-02-01 |
提贝托·布鲁泽塞 |
多不饱和脂肪酸的纯化组合物、其制备方法及其用途
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
EP3219209A1
(de)
|
2016-03-19 |
2017-09-20 |
DMK Deutsches Milchkontor GmbH |
Lagerstabile milchzubereitung enthaltend ascorbinsäure
|
JP7057290B2
(ja)
|
2016-06-27 |
2022-04-19 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
医学的障害を治療するためのキナゾリン及びインドール化合物
|
CA3053818A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
IT201700054543A1
(it)
|
2017-05-19 |
2018-11-19 |
Gleaner Srls |
Preparato come fonte di Omega-3
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
US20190385718A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for lowering triglyceride levels with a concentrated fish oil-based pharmaceutical composition
|
EP3586640A1
(en)
|
2018-06-21 |
2020-01-01 |
Nuseed Pty Ltd |
Dha enriched polyunsaturated fatty acid compositions
|
EP3841086A4
(en)
|
2018-08-20 |
2022-07-27 |
Achillion Pharmaceuticals, Inc. |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
|
JP7020756B2
(ja)
|
2018-09-24 |
2022-02-16 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
対象の心血管イベントのリスクを低減する方法
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|